Recombinant Human SF3B2 293 Cell Lysate
Cat.No. : | SF3B2-1917HCL |
- Specification
- Gene Information
- Related Products
Description : | Antigen standard for splicing factor 3b, subunit 2, 145kDa (SF3B2) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. |
Source : | HEK 293 cells |
Species : | Human |
Components : | This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). |
Size : | 0.1 mg |
Storage Instruction : | Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment. |
Applications : | ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane. |
Gene Name : | SF3B2 splicing factor 3b, subunit 2, 145kDa [ Homo sapiens ] |
Official Symbol : | SF3B2 |
Synonyms : | SF3B2; splicing factor 3b, subunit 2, 145kDa; splicing factor 3b, subunit 2, 145kD; splicing factor 3B subunit 2; Cus1; SAP145; SF3b1; SF3b145; SAP 145; spliceosome associated protein 145; spliceosome-associated protein 145; pre-mRNA splicing factor SF3b 145 kDa subunit; pre-mRNA-splicing factor SF3b 145 kDa subunit; SF3B145; SF3b150; |
Gene ID : | 10992 |
mRNA Refseq : | NM_006842 |
Protein Refseq : | NP_006833 |
MIM : | 605591 |
UniProt ID : | Q13435 |
Chromosome Location : | 11q13 |
Pathway : | Gene Expression, organism-specific biosystem; Processing of Capped Intron-Containing Pre-mRNA, organism-specific biosystem; Spliceosome, organism-specific biosystem; Spliceosome, conserved biosystem; Spliceosome, U2-snRNP, organism-specific biosystem; mRNA Splicing, organism-specific biosystem; mRNA Splicing - Major Pathway, organism-specific biosystem; |
Function : | nucleic acid binding; |
Products Types
◆ Recombinant Protein | ||
Sf3b2-5810M | Recombinant Mouse Sf3b2 Protein, Myc/DDK-tagged | +Inquiry |
SF3B2-1989H | Recombinant Human SF3B2 Protein, His (Fc)-Avi-tagged | +Inquiry |
SF3B2-6004Z | Recombinant Zebrafish SF3B2 | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionThe mutation types of SF3B2 include point mutations, insertions, and deletions. Some of these mutations may cause dysfunction of the spliceosome, while others may affect its interaction with other proteins.
SF3B2 can be detected for mutations by gene sequencing technology. This can help doctors diagnose whether a patient has a condition related to SF3B2 and provide them with a more precise treatment plan.
The effect of SF3B2 mutations on spliceosomes can be analyzed by bioinformatics methods. This can predict its potential effect on the spliceosome by comparing the structure and sequence of mutant and wild-type proteins.
Therapeutic strategies for SF3B2 include inhibiting its expression, modulating its activity, or using gene therapy, among other things. For example, some studies have shown that small molecule inhibitors targeting SF3B2 can inhibit its activity and thus treat some SF3B2-related diseases. In addition, it is also possible to treat related diseases by regulating the expression level of SF3B2.
People with cancers such as medulloblastoma, Wilms tumor, and rhabdomyosarcoma are at high risk of SF3B2 mutations. Genetic testing of these patients can help doctors diagnose the condition more accurately and develop treatment accordingly.
Studies have shown that mutations in the SF3B2 gene are associated with the occurrence of a variety of cancers, such as medulloblastoma, Wilms tumor, rhabdomyosarcoma, etc. These mutations may cause abnormal function of the spliceosome, which in turn affects the normal growth and differentiation of cells.
Customer Reviews (3)
Write a reviewIt has good crystallization properties and is suitable for analysis by X-ray crystallography.
The SF3B2 is easy to store and has no problems with long-term storage.
In special environments, biological activity and structural integrity can be guaranteed.
Ask a Question for All SF3B2 Products
Required fields are marked with *
My Review for All SF3B2 Products
Required fields are marked with *
Inquiry Basket